drugset / Trial / NCT02417870
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
NaSingle-groupOpen-labelTreatment
Summary
To investigate the safety and tolerability of treatment with low dose rIL-2 in renal transplant recipients. To assess the immunologic impact of low dose rIL-2 in renal transplant recipients. To assess the efficacy of low dose rIL-2 in renal transplant recipients.
Timeline
- Start
- 2015-09
- Primary completion
- 2018-04
- Completion
- 2018-04
Outcome
Outcome not reported
Stopped (Business): “lack of funding/resources”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |
Indications
No indication recorded.